Cantargia AB
↗Lund, Sweden
Cantargia AB is a Swedish biotechnology company founded in 2009 based on groundbreaking research from Lund University. The company specializes in the development of antibody-based therapeutics targeting IL1RAP (interleukin-1 receptor accessory protein), a protein expressed on cancer cells and involved in inflammatory diseases. Cantargia's platform addresses tumour-promoting inflammation by simultaneously activating the immune system to destroy cancer cells while blocking pro-inflammatory signals. The company's lead program, nadunolimab (CAN04), is in advanced clinical development for pancreatic cancer, non-small cell lung cancer, and was previously in development for triple-negative breast cancer. In July 2025, Cantargia entered a significant partnership with Otsuka Pharmaceutical, divesting its CAN10 immunology program for autoimmune diseases in a deal worth up to $613 million (including milestone payments), allowing the company to focus its resources on nadunolimab development in oncology.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology and Immunology Therapeutics
SIZE & FINANCIALS
Employees:11-50
Revenue:Not disclosed - Pre-revenue clinical stage company
Founded:2009
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:Fenja Capital, Lubio Science
STOCK
Exchange:Nasdaq Stockholm
Ticker:CANTA
Market Cap:~851.5M SEK (approximately $80-90M USD at current exchange rates)
PIPELINE
Stage:Phase 1 - Phase 2
Lead Drug Stage:Phase 2/Phase IIb
Modalities:Monoclonal Antibodies, mAb
Active Trials:4
Trial Phases:Phase 1: 1 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Otsuka Pharmaceutical Co., Ltd., Glycotope Biotechnology (now Celonic AG), Patheon Biologics, BioInvent International AB, MD Anderson Cancer Center, Lund University
COMPETITION
Position:Niche Player - Leader in IL1RAP-targeted therapeutics
Competitors:GSK (Immuno-oncology programs targeting tumor microenvironment), Merck (IL-6 targeting approaches), BeiGene (Cancer immunotherapy), Affimed (Innate cell engager technology), Turnstone Biologics (TIL therapy), Other IL-1 pathway inhibitors in development (broader category)
LEADERSHIP
Key Executives:
Dr. Hilde Hermansen Steineger - Chief Executive Officer
David Liberg - Chief Scientific Officer
Patrik Renblad - Chief Financial Officer
Ton Berkien - Chief Business Officer
Scientific Founders:Thoas Fioretos, Marcus Järås, Kjell Sjöström
Board Members:Damian Marron (Non-Executive Director & Chair of Remuneration Committee), Jenny Sundqvist (Board Member), Flavia Borellini (Board Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cantargia AB. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.